BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 21987825)

  • 1. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.
    Yamamoto-Sugitani M; Kuroda J; Ashihara E; Nagoshi H; Kobayashi T; Matsumoto Y; Sasaki N; Shimura Y; Kiyota M; Nakayama R; Akaji K; Taki T; Uoshima N; Kobayashi Y; Horiike S; Maekawa T; Taniwaki M
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17468-73. PubMed ID: 21987825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
    Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
    Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
    Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells.
    Nakayama R; Kuroda J; Taniyama N; Yamamoto-Sugitani M; Wada S; Kiyota M; Mizutani S; Chinen Y; Matsumoto Y; Nagoshi H; Shimura Y; Kobayashi T; Horiike S; Sato K; Taniwaki M
    Leuk Res; 2014 Jan; 38(1):103-8. PubMed ID: 23953881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
    Dazzi F; Capelli D; Hasserjian R; Cotter F; Corbo M; Poletti A; Chinswangwatanakul W; Goldman JM; Gordon MY
    Blood; 1998 Aug; 92(4):1390-6. PubMed ID: 9694728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
    Raimondo S; Saieva L; Corrado C; Fontana S; Flugy A; Rizzo A; De Leo G; Alessandro R
    Cell Commun Signal; 2015 Feb; 13():8. PubMed ID: 25644060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
    Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
    Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
    Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
    Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
    Kuroda J; Yamamoto M; Nagoshi H; Kobayashi T; Sasaki N; Shimura Y; Horiike S; Kimura S; Yamauchi A; Hirashima M; Taniwaki M
    Mol Cancer Res; 2010 Jul; 8(7):994-1001. PubMed ID: 20571063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
    Hao SX; Ren R
    Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
    Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
    Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF-α-induced alterations in stromal progenitors enhance leukemic stem cell growth via CXCR2 signaling.
    Agarwal P; Li H; Choi K; Hueneman K; He J; Welner RS; Starczynowski DT; Bhatia R
    Cell Rep; 2021 Jul; 36(2):109386. PubMed ID: 34260914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway.
    Hu K; Gu Y; Lou L; Liu L; Hu Y; Wang B; Luo Y; Shi J; Yu X; Huang H
    J Hematol Oncol; 2015 Jan; 8():1. PubMed ID: 25622682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.